Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52 Week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

NCT01316939 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01316939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01316939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52 Week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Terminated
Start date
May 9, 2011
Completion date
October 23, 2013
Enrollment
229 (actual)
Sites
256

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease